Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI

• Colleen S. Kraft,
• Matthew Sims,
• Michael Silverman,
• Thomas J. Louie,
• Paul Feuerstadt,
• Edward S. Huang,
• Sahil Khanna,
• Charles S. Berenson,
• Elaine E. L. Wang,
• Stuart H. Cohen,
• Louis Korman,
• Christine Lee,
• Colleen R. Kelly,
• Alberto Odio,
• Paul P. Cook,
• Bret Lashner,
• Mayur Ramesh,
• Princy Kumar,
• Ananya De,
• Asli Memisoglu,
• David A. Lombardi,
• Brooke R. Hasson,
• Barbara H. McGovern,
• Lisa von Moltke,
• Darrell S. Pardi,
• on behalf of the ECOSPOR III and ECOSPOR IV investigators

Affiliations

Colleen S. Kraft

Department of Pathology and Laboratory Medicine, Division of Infectious Diseases, Emory University

Matthew Sims

Section of Infectious Diseases and International Medicine, Department of Internal Medicine, Beaumont Royal Oak

Michael Silverman

Western University

Thomas J. Louie

Cumming School of Medicine, University of Calgary

Paul Feuerstadt

Division of Digestive Disease, Yale University School of Medicine

Edward S. Huang

Department of Gastroenterology, Palo Alto Medical Foundation, Sutter Health

Sahil Khanna

Division of Gastroenterology and Hepatology, Mayo Clinic

Charles S. Berenson

University at Buffalo, VA Western New York Healthcare System

Elaine E. L. Wang

Seres Therapeutics

Stuart H. Cohen

University of California Davis Health

Louis Korman

Gastroenterology and Hepatology, Chevy Chase Clinical Research

Christine Lee

Island Medical Program, University of British Columbia and University of Victoria

Colleen R. Kelly

Division of Gastroenterology, Brigham and Women’s Hospital

Alberto Odio

Adventist Health

Paul P. Cook

Brody School of Medicine at East, Carolina University

Bret Lashner

Cleveland Clinic

Mayur Ramesh

Division of Infectious Diseases, Henry Ford Health

Princy Kumar

Division of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center

Ananya De

Seres Therapeutics

Asli Memisoglu

Seres Therapeutics

David A. Lombardi

Seres Therapeutics

Brooke R. Hasson

Seres Therapeutics

Barbara H. McGovern

Seres Therapeutics

Lisa von Moltke

Seres Therapeutics

Darrell S. Pardi

Division of Gastroenterology and Hepatology, Mayo Clinic

on behalf of the ECOSPOR III and ECOSPOR IV investigators